当前位置： SCI文献检索 > NEURO-ONCOLOGY期刊下所有文献 > Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study.

Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study.

Abstract：

:We explored the feasibility of concurrent palliative chemotherapy and low-dose fractionated radiotherapy (LD-FRT) in glioblastoma multiforme (GBM). Patients with recurrent/progressive GBM at least 3 months after the end of primary radiotherapy received 0.3 Gy twice daily with cisplatin and fotemustine if progressing on temozolomide, or 0.4 Gy twice daily with temozolomide if recurrent 4-6 months later (retreatment group). Newly diagnosed GBM with gross residual mass received 30 Gy with concomitant and adjuvant temozolomide and 0.4 Gy twice daily from the second adjuvant cycle (naive group) for 2-4 cycles. Twenty-six patients were enrolled. In the retreatment group (n = 17; median LD-FRT total dose 7.2 Gy [range 2.4-11.6]), grade 3 or 4 hematological toxicity was observed in 5.9% of patients. Median follow-up time was 20 months (range 4-35). Median progression-free survival (PFS) and overall survival (OS) from the time of recurrence or progression were 4 and 8 months, respectively (OS at 6 months, 69%; at 12 months, 16.7%). In the naive group (n = 9; median LD-FRT total dose 8 Gy [range 3.2-16]), grade 3 or 4 hematological toxicity was observed in 11.1% of patients. Median follow-up time was 17 months (range 8-20)-median PFS was 9 months, with PFS at 6 months and at 1 year of 66.7% and 26.7%, respectively; and median OS was 12 months, with OS at 6 months and at 1 year of 77.8% and 34.6%, respectively. LD-FRT with concurrent chemotherapy was well tolerated.

journal_name

Neuro Oncol

journal_title

Neuro-oncology

authors

Balducci M,Chiesa S,Diletto B,D'Agostino GR,Mangiola A,Manfrida S,Mantini G,Albanese A,Fiorentino A,Frascino V,De Bari B,Micciche' F,De Rose F,Morganti AG,Anile C,Valentini V

doi

10.1093/neuonc/nor173

subject

Has Abstract

pub_date

2012-01-01 00:00:00

pages

79-86

issue

1

eissn

1522-8517

issn

1523-5866

pii

nor173

journal_volume

14

pub_type

杂志文章

相关文献

NEURO-ONCOLOGY文献大全
  • Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status.

    abstract：BACKGROUND:Glioblastomas with a specific mutation in the isocitrate dehydrogenase 1 (IDH1) gene have a better prognosis than gliomas with wild-type IDH1. METHODS:Here we compare the IDH1 mutational status in 172 contrast-enhancing glioma patients with the invasion profile generated by a patient-specific mathematical m...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/nou027

    authors： Baldock AL,Yagle K,Born DE,Ahn S,Trister AD,Neal M,Johnston SK,Bridge CA,Basanta D,Scott J,Malone H,Sonabend AM,Canoll P,Mrugala MM,Rockhill JK,Rockne RC,Swanson KR

    更新日期：2014-06-01 00:00:00

  • Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy.

    abstract：:The individualized care of glioma patients ought to benefit from imaging biomarkers as precocious predictors of therapeutic efficacy. Contrast enhanced MRI and [(18)F]-fluorodeoxyglucose (FDG)-PET are routinely used in clinical settings; their ability to forecast the therapeutic response is controversial. The objectiv...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/nos260

    authors： Corroyer-Dulmont A,Pérès EA,Petit E,Guillamo JS,Varoqueaux N,Roussel S,Toutain J,Divoux D,MacKenzie ET,Delamare J,Ibazizène M,Lecocq M,Jacobs AH,Barré L,Bernaudin M,Valable S

    更新日期：2013-01-01 00:00:00

  • PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor.

    abstract：:We investigated the activation of platelet-derived growth factor (PDGF) receptor A (PDGFRA), PDGF receptor B (PDGFRB), epidermal growth factor receptor (EGFR), and their downstream pathways in malignant peripheral nerve sheath tumors (MPNSTs). PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogen...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1215/15228517-2009-003

    authors： Perrone F,Da Riva L,Orsenigo M,Losa M,Jocollè G,Millefanti C,Pastore E,Gronchi A,Pierotti MA,Pilotti S

    更新日期：2009-12-01 00:00:00

  • VAMP8 facilitates cellular proliferation and temozolomide resistance in human glioma cells.

    abstract：BACKGROUND:Malignant glioma is a common and lethal primary brain tumor in adults. Here we identified a novel oncoprotein, vesicle-associated membrane protein 8 (VAMP8), and investigated its roles in tumorigenisis and chemoresistance in glioma. METHODS:The expression of gene and protein were determined by quantitative P...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/nou219

    authors： Chen Y,Meng D,Wang H,Sun R,Wang D,Wang S,Fan J,Zhao Y,Wang J,Yang S,Huai C,Song X,Qin R,Xu T,Yun D,Hu L,Yang J,Zhang X,Chen H,Chen J,Chen H,Lu D

    更新日期：2015-03-01 00:00:00

  • Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.

    abstract：BACKGROUND:Anaplastic oligodendroglial tumors are rare, and median survival varies widely. Analysis of 1p19q deletion is performed commonly and is an important prognostic factor. However, age and other clinical variables also carry prognostic value, and it is unclear how to incorporate them into clinical decision makin...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/nou083

    authors： Panageas KS,Reiner AS,Iwamoto FM,Cloughesy TF,Aldape KD,Rivera AL,Eichler AF,Louis DN,Paleologos NA,Fisher BJ,Ashby LS,Cairncross JG,Urgoiti GB,Wen PY,Ligon KL,Schiff D,Robins HI,Rocque BG,Chamberlain MC,Mason WP,

    更新日期：2014-11-01 00:00:00

  • Diet and risk of glioma: combined analysis of 3 large prospective studies in the UK and USA.

    abstract：BACKGROUND:Available evidence on diet and glioma risk comes mainly from studies with retrospective collection of dietary data. To minimize possible differential dietary recall between those with and without glioma, we present findings from 3 large prospective studies. METHODS:Participants included 692 176 from the UK ...

    journal_title：Neuro-oncology

    pub_type： 杂志文章,meta分析

    doi：10.1093/neuonc/noz013

    authors： Kuan AS,Green J,Kitahara CM,De González AB,Key T,K Reeves G,Floud S,Balkwill A,Bradbury K,Liao LM,Freedman ND,Beral V,Sweetland S,Million Women Study, the NIH-AARP study, and the PLCO study.

    更新日期：2019-07-11 00:00:00

  • Coexpression of neuronatin splice forms promotes medulloblastoma growth.

    abstract：:Medulloblastoma (MB) is the most common pediatric brain cancer. Several important developmental pathways have been implicated in MB formation, but fewer therapeutic targets have been identified. To locate frequently overexpressed genes, we performed a comprehensive gene expression survey of MB. Our comparison of 20 pr...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1215/15228517-2008-038

    authors： Siu IM,Bai R,Gallia GL,Edwards JB,Tyler BM,Eberhart CG,Riggins GJ

    更新日期：2008-10-01 00:00:00

  • An epidemiology report for primary central nervous system tumors in adolescents and young adults: a nationwide population-based study in France, 2008-2013.

    abstract：BACKGROUND:Primary central nervous system tumors (PCNST) among adolescents and young adults (AYA, 15-39 y) have rarely been reported. We present a nationwide report of PCNST histologically confirmed in the French AYA population between 2008 and 2013. METHODS:Patients were identified through the French Brain Tumor Data...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/noz227

    authors： Ng S,Zouaoui S,Bessaoud F,Rigau V,Roux A,Darlix A,Bauchet F,Mathieu-Daudé H,Trétarre B,Figarella-Branger D,Pallud J,Frappaz D,Roujeau T,Bauchet L

    更新日期：2020-06-09 00:00:00

  • Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.

    abstract：:Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF) that has efficacy in recurrent malignant gliomas, particularly in combination with irinotecan. However, responses are rarely durable. Continuation of bevacizumab in combination with another chemotherapeutic agent may demon...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1215/15228517-2009-006

    authors： Quant EC,Norden AD,Drappatz J,Muzikansky A,Doherty L,Lafrankie D,Ciampa A,Kesari S,Wen PY

    更新日期：2009-10-01 00:00:00

  • Diffusion radiomics as a diagnostic model for atypical manifestation of primary central nervous system lymphoma: development and multicenter external validation.

    abstract：Background:Radiomics is a rapidly growing field in neuro-oncology, but studies have been limited to conventional MRI, and external validation is critically lacking. We evaluated technical feasibility, diagnostic performance, and generalizability of a diffusion radiomics model for identifying atypical primary central ne...

    journal_title：Neuro-oncology

    pub_type： 杂志文章,多中心研究

    doi：10.1093/neuonc/noy021

    authors： Kang D,Park JE,Kim YH,Kim JH,Oh JY,Kim J,Kim Y,Kim ST,Kim HS

    更新日期：2018-08-02 00:00:00

  • Serum-free culture success of glial tumors is related to specific molecular profiles and expression of extracellular matrix-associated gene modules.

    abstract：BACKGROUND:Recent molecular characterization studies have identified clinically relevant molecular subtypes to coexist within the same histological entities of glioma. Comparative studies between serum-supplemented and serum-free (SF) culture conditions have demonstrated that SF conditions select for glioma stem-like c...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/not116

    authors： Balvers RK,Kleijn A,Kloezeman JJ,French PJ,Kremer A,van den Bent MJ,Dirven CM,Leenstra S,Lamfers ML

    更新日期：2013-12-01 00:00:00

  • Invasion patterns in brain metastases of solid cancers.

    abstract：BACKGROUND:Brain metastases are generally considered to be well demarcated from the surrounding brain parenchyma, although infiltrative growth patterns have been observed. We systemically investigated infiltration patterns and expression of adhesion molecules in a large and well-defined series of autopsy cases of brain...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/not112

    authors： Berghoff AS,Rajky O,Winkler F,Bartsch R,Furtner J,Hainfellner JA,Goodman SL,Weller M,Schittenhelm J,Preusser M

    更新日期：2013-12-01 00:00:00

  • A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool.

    abstract：BACKGROUND:Glioblastoma multiforme (GBM) is the most frequent malignant brain tumor in adults, and its prognosis remains dismal despite intensive research and therapeutic advances. Diagnostic biomarkers would be clinically meaningful to allow for early detection of the tumor and for those cases in which surgery is cont...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/not218

    authors： Manterola L,Guruceaga E,Gállego Pérez-Larraya J,González-Huarriz M,Jauregui P,Tejada S,Diez-Valle R,Segura V,Samprón N,Barrena C,Ruiz I,Agirre A,Ayuso A,Rodríguez J,González A,Xipell E,Matheu A,López de Munain A,Tuñón

    更新日期：2014-04-01 00:00:00

  • Serial MR diffusion to predict treatment response in high-grade pediatric brain tumors: a comparison of regional and voxel-based diffusion change metrics.

    abstract：BACKGROUND:Assessment of treatment response by measuring tumor size is known to be a late and potentially confounded response index. Serial diffusion MRI has shown potential for allowing earlier and possibly more reliable response assessment in adult patients, with limited experience in clinical settings and in pediatr...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/not034

    authors： Rodriguez Gutierrez D,Manita M,Jaspan T,Dineen RA,Grundy RG,Auer DP

    更新日期：2013-08-01 00:00:00

  • Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma.

    abstract：:Allergies and the use of anti-inflammatory medication appear to be associated with reduced glioblastoma risk. However, these observations may merely reflect systemic immunosuppression induced by the tumor. To better understand the effect of this tumor on allergies and inflammation, we used CD133 mRNA expression as an ...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/nop035

    authors： Schwartzbaum JA,Huang K,Lawler S,Ding B,Yu J,Chiocca EA

    更新日期：2010-04-01 00:00:00

  • A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors.

    abstract：:Glial tumors with oligodendroglial components are considered chemo-responsive. Forty newly diagnosed patients (11 anaplastic oligodendrogliomas [OD] and 29 anaplastic oligoastrocytomas [OA]) were enrolled into this multicenter, open-label, single-arm Phase II trial of first-line temozolomide (200 mg/m(2) on days 1-5 e...

    journal_title：Neuro-oncology

    pub_type： 杂志文章,多中心研究

    doi：10.1093/neuonc/nop065

    authors： Gan HK,Rosenthal MA,Dowling A,Kalnins R,Algar E,Wong N,Benson A,Woods AM,Cher L

    更新日期：2010-05-01 00:00:00

  • Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium.

    abstract：BACKGROUND:Diffuse intrinsic pontine glioma (DIPG) is associated with poor survival regardless of therapy. We used volumetric apparent diffusion coefficient (ADC) histogram metrics to determine associations with progression-free survival (PFS) and overall survival (OS) at baseline and after radiation therapy (RT). MET...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/nov256

    authors： Poussaint TY,Vajapeyam S,Ricci KI,Panigrahy A,Kocak M,Kun LE,Boyett JM,Pollack IF,Fouladi M

    更新日期：2016-05-01 00:00:00

  • Tailoring neurophysiological strategies with clinical context enhances resection and safety and expands indications in gliomas involving motor pathways.

    abstract：BACKGROUND:Resection of motor pathway gliomas requires the intraoperative recognition of essential cortical-subcortical motor structures. The degree of involvement of motor structures is variable, and increases as result of treatments patients are submitted to. Intraoperative neurophysiology offers various stimulation ...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/not327

    authors： Bello L,Riva M,Fava E,Ferpozzi V,Castellano A,Raneri F,Pessina F,Bizzi A,Falini A,Cerri G

    更新日期：2014-08-01 00:00:00

  • MRI contrast agent for targeting glioma: interleukin-13 labeled liposome encapsulating gadolinium-DTPA.

    abstract：BACKGROUND:Detection of glioma with MRI contrast agent is limited to cases in which the blood-brain barrier (BBB) is compromised as contrast agents cannot cross the BBB. Thus, an early-stage infiltrating tumor is not detectable. Interleukin-13 receptor alpha 2 (IL-13Rα2), which has been shown to be overexpressed in gli...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/nov263

    authors： Liu X,Madhankumar AB,Miller PA,Duck KA,Hafenstein S,Rizk E,Slagle-Webb B,Sheehan JM,Connor JR,Yang QX

    更新日期：2016-05-01 00:00:00

  • Co-polysomy of chromosome 1q and 19p predicts worse prognosis in 1p/19q codeleted oligodendroglial tumors: FISH analysis of 148 consecutive cases.

    abstract：BACKGROUND:This study aimed to evaluate the prognostic significance of co-polsomy of chromosome 1q and 19p in 1p/19q codeleted oligodendroglial tumors (ODGs). METHODS:In a series of 148 ODGs with 1p/19q deletion, co-polysomy of 1q and 19p was detected by fluorescence in situ hybridization (FISH). Log-rank analysis and...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/not092

    authors： Ren X,Jiang H,Cui X,Cui Y,Ma J,Jiang Z,Sui D,Lin S

    更新日期：2013-09-01 00:00:00

  • Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas.

    abstract：:PDGFRA is a critical gene in glioma biology. Similar to EGFR, PDGFRA has been shown to be overexpressed, amplified, mutated, or truncated in gliomas, particularly glioblastomas. In addition, PDGFRA has been recently shown to be rearranged in glioblastoma. However, the frequency, cooccurrence, and clinical value of PDG...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/nos217

    authors： Alentorn A,Marie Y,Carpentier C,Boisselier B,Giry M,Labussière M,Mokhtari K,Hoang-Xuan K,Sanson M,Delattre JY,Idbaih A

    更新日期：2012-11-01 00:00:00

  • High failure rate in spinal ependymomas with long-term follow-up.

    abstract：:Data on spinal ependymomas are sparse, and prognostic factors remain controversial. The primary aim of this study is to review a historical cohort, with large patient numbers and long follow-up, and provide estimates of time to progression (TTP) and survival after progression. As a secondary aim, we assess the effects...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1215/S1152851704001231

    authors： Gomez DR,Missett BT,Wara WM,Lamborn KR,Prados MD,Chang S,Berger MS,Haas-Kogan DA

    更新日期：2005-07-01 00:00:00

  • A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy.

    abstract：BACKGROUND:Fatigue is common among glioma patients undergoing radiotherapy (RT) and impacts quality of life (QOL). We evaluated whether armodafinil, a wakefulness-promoting medication, improves fatigue in glioma patients undergoing RT. METHODS:Eligibility criteria included age ≥18 years, Karnofsky performance status ≥...

    journal_title：Neuro-oncology

    pub_type： 杂志文章,随机对照试验

    doi：10.1093/neuonc/now007

    authors： Lee EQ,Muzikansky A,Drappatz J,Kesari S,Wong ET,Fadul CE,Reardon DA,Norden AD,Nayak L,Rinne ML,Alexander BM,Arvold ND,Doherty L,Stefanik J,LaFrankie D,Ruland SF,Pulverenti J,Smith KH,Gaffey SC,Hammond S,Wen PY

    更新日期：2016-06-01 00:00:00

  • Understanding brain penetrance of anticancer drugs.

    abstract：:This paper explicates the impact of tumor capillary permeability for glioma World Health Organization (WHO) grades II to IV on brain-penetrant drug entry and distribution within the tumor and the brain adjacent to tumor (leading edge). In addition, we consider the distribution of non-brain penetrant drugs and how, in ...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/noy018

    authors： Levin VA,Ellingson BM

    更新日期：2018-04-09 00:00:00

  • A novel tumor-promoting role for nuclear factor IA in glioblastomas is mediated through negative regulation of p53, p21, and PAI1.

    abstract：:Background Nuclear factor IA (NFIA), a transcription factor and essential regulator in embryonic glial development, is highly expressed in human glioblastoma (GBM) compared with normal brain, but its contribution to GBM and cancer pathogenesis is unknown. Here we demonstrate a novel role for NFIA in promoting growth a...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/not167

    authors： Lee JS,Xiao J,Patel P,Schade J,Wang J,Deneen B,Erdreich-Epstein A,Song HR

    更新日期：2014-01-01 00:00:00

  • Biology and management of ependymomas.

    abstract：:Ependymomas are rare primary tumors of the central nervous system in children and adults that comprise histologically similar but genetically distinct subgroups. The tumor biology is typically more associated with the site of origin rather than being age-specific. Genetically distinct subgroups have been identified by...

    journal_title：Neuro-oncology

    pub_type： 杂志文章,评审

    doi：10.1093/neuonc/now016

    authors： Wu J,Armstrong TS,Gilbert MR

    更新日期：2016-07-01 00:00:00

  • Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?

    abstract：:A phase I trial of an engineered poliovirus for the treatment of recurrent glioblastoma (GBM) has attracted attention due to 8 survivors reaching the 24-month and 5 reaching the 36-month survival landmarks.1 Genetically engineered viruses (oncolytic viruses) have been in trials for GBM for almost two decades.2 These r...

    journal_title：Neuro-oncology

    pub_type： 杂志文章,评审

    doi：10.1093/neuonc/noy170

    authors： Chiocca EA,Nassiri F,Wang J,Peruzzi P,Zadeh G

    更新日期：2019-01-01 00:00:00

  • Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

    abstract：Background:Platelet-derived growth factor (PDGF) signaling is important in gliomagenesis and PDGF receptor-β is expressed on most endothelial cells in glioblastoma specimens. Methods:We report the results of feasibility, phase I, and phase II studies of tandutinib (MLN518), an orally bioavailable inhibitor of type III...

    journal_title：Neuro-oncology

    pub_type： 杂志文章,多中心研究

    doi：10.1093/neuonc/now185

    authors： Batchelor TT,Gerstner ER,Ye X,Desideri S,Duda DG,Peereboom D,Lesser GJ,Chowdhary S,Wen PY,Grossman S,Supko JG

    更新日期：2017-04-01 00:00:00

  • Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells.

    abstract：Background:CNS tumors, including medulloblastoma and pediatric glioblastoma (pGBM) account for the majority of solid pediatric malignancies. There remains an unmet need to identify novel treatment approaches in poor prognosis and relapsed pediatric brain tumors, where therapeutic options are limited. Small-molecule B-c...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/nox134

    authors： Levesley J,Steele L,Brüning-Richardson A,Davison A,Zhou J,Ding C,Lawler S,Short SC

    更新日期：2018-01-22 00:00:00

  • A low percentage of metastases in deep brain and temporal lobe structures.

    abstract：BACKGROUND:Whole-brain radiotherapy (WBRT) in patients with brain metastases (BM) is associated with neurocognitive decline. Given its crucial role in learning and memory, efforts to mitigate this toxicity have mostly focused on sparing radiation to the hippocampus. We hypothesized that BM are not evenly distributed ac...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/noz023

    authors： Yanagihara TK,McFaline-Figueroa JR,Giacalone NJ,Lee AW,Soni V,Hwang ME,Hsieh KT,Saraf A,Wu CC,Yang D,Wen PY,Ashamalla H,Aizer AA,Wang TJC,Huang RY

    更新日期：2019-05-06 00:00:00